Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Typbar-TCV
- Development stage
- Unknown
- Lead developer
- Bharat Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Typbar-TCV** is Bharat Biotech's single-antigen typhoid conjugate vaccine for active immunization against typhoid fever caused by *Salmonella enterica* serovar Typhi. Each 0.5 mL dose contains 25 micrograms of purified Vi capsular polysaccharide from *S. Typhi* Ty2 covalently conjugated to tetanus toxoid. Conjugation converts the otherwise largely T-cell-independent polysaccharide response into a T-cell-dependent anti-Vi immune response, supporting higher-affinity antibodies and immunologic memory. It is administered as a single intramuscular dose and is WHO-prequalified. ([extranet.who.int](https://extranet.who.int/prequal/sites/default/files/vwa_vaccine/pq_319_320_TypbarTCV_BBIL_PI-2022.pdf))
- Brand names
- Typbar-TCV
- Other names
- typhoid conjugate vaccine (Vi-tetanus toxoid)Vi-tetanus toxoid conjugate vaccineTCV (typhoid conjugate vaccine)
02
Targets
TT (Tetanus toxoid)Vi antigen (Vi capsular polysaccharide)
Beyond the preview
Go deeper on Typbar-TCV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Typbar-TCV.